Teva Pharmaceutical Industries Limited

TEVA | NYSE

Price Alert Chart Builder DCF Calculator

$39.87

-$0.19 (-0.47%)

Sep 22, 2026, 11:25 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.47%

(1D)

Rating

Updated: Aug 18, 2026

50.4

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $46.43B

1D Range

39.32 40.11

52W Range

18.21 40.79

Valuation (TTM)

PE 66.77

PB 6.01

EV/EBITDA 19.88

Valuation (NTM)

Forward PE 12.80

Forward PEG 1.16

Price Target $44.75

Cash Flow

FCF Yield 3.2%

SBC Adj. FCF Yield 2.9%

SBC Impact -8.6%

Margins

Gross Margin 52.5%

Operating Margin 11.4%

FCF Margin 8.6%

Growth (CAGR)

Revenue 3Y | 5Y 4.9% | 1.2%

Dil EPS 3Y | 5Y 2970.0% | 84.9%

FCF 3Y | 5Y 8.4% | 18.6%

Returns

ROA 1.8%

ROE 9.2%

ROIC 9.0%

Financial Health

Net Debt

$12.94B

Current Ratio 0.88

Interest Coverage 2.99

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, a...

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

Employees 32,008

IPO Date Feb 15, 1982

Website www.tevapharm.com

Fiscal Year January - December

Full Company Profile

Latest News

8 hours ago · seekingalpha.com

Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript

10 hours ago · marketbeat.com

Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline

Teva Pharmaceutical Industries NYSE: TEVA Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operations.

1 day ago · businesswire.com

Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026

MONTPELLIER, France--(BUSINESS WIRE)--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's proprietary BEPO® technology, licensed to Teva as SteadyTeq™. The findings were presented at Psych Congress 2026, held from September 15 to 19 in New Orleans, Louisiana. Teva presented new post hoc analyses from the Phase 3 SOLARIS trial evaluating its investigational once-monthly subcutaneous olanzapine LAI.

3 days ago · globenewswire.com

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older patients (aged ≥55 years). The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.

3 days ago · globenewswire.com

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension. The results demonstrate how UZEDY helps patients with schizophrenia remain on treatment longer while reducing emergency care and healthcare costs compared with other treatment options. The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.

3 days ago · globenewswire.com

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-'749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLARIS data highlighted the acute and long-term durability, efficacy and safety of TEV-'749 as a once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults. The findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.

6 days ago · schaeffersresearch.com

Most Active Options Report: FPS, TEVA, AFL

These three stocks are seeing some of the most unusual options volume today

7 days ago · benzinga.com

Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) had a busy week that included a major debt refinancing, a milestone shift in how its shares trade on the NYSE and analyst activity.

8 days ago · marketbeat.com

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform

Teva Pharmaceutical Industries NYSE: TEVA CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility.